stockrow
Saturday 7 November 2026
Export GRCE’s income statement to Excel — free account
Grace Therapeutics, Inc.
GRCE Healthcare Biotechnology
- EPS
- −333.3%
- Free cash flow
- −78.9%
Quarter to June 2026, against a year earlier
1.86
0.08
+4.49%
Follow GRCE
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (36.19%) | (11.94%) | (10.22%) | (13.15%) |
+8 more TTM periods Free account |
|
| (33.74%) | (11.24%) | (9.22%) | (11.85%) | ||
ROIC |
(43.36%) | (14.76%) | (15.21%) | (17.01%) | |
Return on Tangible Assets |
(154.48%) | (51.13%) | (33.33%) | (48.67%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.60) | (0.54) | (0.60) | (0.75) | |
Free Cash Flow |
(10.29) | (8.87) | (10.13) | (12.01) | |
| Other line items | |||||
Cash ROIC |
(16.60%) | (10.97%) | (12.12%) | (15.08%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.51 | 1.14 | 1.69 | 1.54 | |
Depreciation/Fixed assets |
1.00 | 0.88 | 0.64 | 0.50 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.60) | (0.54) | (0.60) | (0.75) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 2 Nov 2026